These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 38942215

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Thymic epithelial tumors: From biology to treatment.
    Conforti F, Pala L, Giaccone G, De Pas T.
    Cancer Treat Rev; 2020 Jun; 86():102014. PubMed ID: 32272379
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Thymic epithelial tumor medical treatment: A narrative review.
    Huang Q, Zhu L, Liu Y, Zhang Y.
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189167. PubMed ID: 39117091
    [Abstract] [Full Text] [Related]

  • 6. Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.
    Ao YQ, Gao J, Wang S, Jiang JH, Deng J, Wang HK, Xu B, Ding JY.
    Mol Cancer; 2023 Apr 13; 22(1):70. PubMed ID: 37055838
    [Abstract] [Full Text] [Related]

  • 7. Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors.
    Yamamoto Y, Iwahori K, Funaki S, Matsumoto M, Hirata M, Yoshida T, Kanzaki R, Kanou T, Ose N, Minami M, Sato E, Kumanogoh A, Shintani Y, Okumura M, Wada H.
    Sci Rep; 2020 Mar 04; 10(1):4064. PubMed ID: 32132638
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review.
    Song X, Fan J, Zhu L, Wang Z, He Y, Zhou C.
    J Thorac Dis; 2021 Aug 04; 13(8):5093-5103. PubMed ID: 34527346
    [Abstract] [Full Text] [Related]

  • 15. Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
    Arbour KC, Naidoo J, Steele KE, Ni A, Moreira AL, Rekhtman N, Robbins PB, Karakunnel J, Rimner A, Huang J, Riely GJ, Hellmann MD.
    PLoS One; 2017 Aug 04; 12(8):e0182665. PubMed ID: 28771603
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials.
    Conforti F, Pala L, De Pas T, He Y, Giaccone G.
    Expert Opin Investig Drugs; 2022 Sep 04; 31(9):895-904. PubMed ID: 35961945
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.